Finally, the M.D. Anderson Cancer Center is sponsoring a phase I clinical trial to test the safety and highest tolerable dose of siRNA-EPHA2-DOPC for patients with advanced, recurrent ovarian cancer [122]. Here, EPHA2 is linked to ovarian carcinoma.